NOVATEK

Pre-Annual General Meeting Information • Nov 15, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4500H

PAO Novatek

15 November 2018

FOR IMMEDIATE RELEASE

NOVATEK's Board оf Directors Approved Agenda for the Extraordinary General Meeting of Shareholders

Moscow, 15 November 2018. The Board of Directors (the "Board") of PAO NOVATEK ("NOVATEK" and/or the "Company") approved the following agenda for the Company's Extraordinary General Meeting of Shareholders ("EGM") convened for 18 January 2019:

1.   Early termination of authorities of the members of NOVATEK's Board of Directors.

2.   Election of members of NOVATEK's Board of Directors.

The list of persons entitled to take part in NOVATEK's EGM will be compiled as of 26 November 2018.

***

For further information, please visit www.novatek.ru or contact:

Press Service +7 (495) 721 2207 press@novatek.ru	Investor Relations +7 (495) 730 6013 IR@novatek.ru

***

PAO NOVATEK is one of the largest independent natural gas producers in Russia, and in 2017, entered the global gas market by successfully launching the Yamal LNG project. Founded in 1994, the Company is engaged in the exploration, production, processing and marketing of natural gas and liquid hydrocarbons. The Company's upstream activities are concentrated mainly in the prolific Yamal-Nenets Autonomous Region, which is the world's largest natural gas producing area and accounts for approximately 80% of Russia's natural gas production and approximately 15% of the world's gas production. NOVATEK is a public joint stock company established under the laws of the Russian Federation. The Company's shares are listed in Russia on Moscow Exchange (MOEX) and the London Stock Exchange (LSE) under the ticker symbol «NVTK».

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBABFTMBABMAP